HCPCS drug code · CMS crosswalk
Ondansetron ODT HCPCS Code
In short
Ondansetron ODT is billed under HCPCS Q0162 — Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen. One billing unit is 1 mg. CMS's crosswalk lists 55 Ondansetron ODT NDCs under this code.
Reference
- Q0162
- Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimenBilling unit: 1 mg
- Labelers
- A-S Medication Solutions; BluePoint Laboratories; Chartwell; Glenmark Pharmaceuticals Inc., USA; Lifsa Drugs LLC; Northstar RxLLC; PD-Rx Pharmaceuticals, Inc.; PREFERRED PHARMACEUTICALS, INC.and 1 more
Medicare Part B payment limit
CMS ASP filePayment limit per unit$0.016
Per1 mg
Coinsurance20%
Effective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Ondansetron ODT units and claim line
Enter the dose given to get the Q0162 units and the NDC line for the CMS-1500 and the 837P.
Enter the dose given to build the claim line.
Ondansetron ODT NDCs and billing units
From CMS’s ASP NDC–HCPCS crosswalk, effective October 1, 2026 through December 31, 2026. Billing units per package are CMS’s figures for the code’s unit.
| NDC (11-digit) | HCPCS | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| 16714-0200-30 | Q0162 | Northstar RxLLC | 30 | 120 |
| 16714-0201-10 | Q0162 | Northstar RxLLC | 10 | 80 |
| 16714-0201-30 | Q0162 | Northstar RxLLC | 30 | 240 |
| 43063-0857-02 | Q0162 | PD-Rx Pharmaceuticals, Inc. | 2 | 8 |
| 43063-0857-04 | Q0162 | PD-Rx Pharmaceuticals, Inc. | 4 | 16 |
| 43063-0857-05 | Q0162 | PD-Rx Pharmaceuticals, Inc. | 5 | 20 |
| 43063-0857-06 | Q0162 | PD-Rx Pharmaceuticals, Inc. | 6 | 24 |
| 43063-0857-10 | Q0162 | PD-Rx Pharmaceuticals, Inc. | 10 | 40 |
| 43063-0857-20 | Q0162 | PD-Rx Pharmaceuticals, Inc. | 20 | 80 |
| 43063-0870-04 | Q0162 | PD-Rx Pharmaceuticals, Inc. | 4 | 32 |
| 43063-0870-10 | Q0162 | PD-Rx Pharmaceuticals, Inc. | 10 | 80 |
| 50090-1128-01 | Q0162 | A-S Medication Solutions | 30 | 240 |
| 50090-1200-00 | Q0162 | A-S Medication Solutions | 10 | 40 |
| 50090-1200-01 | Q0162 | A-S Medication Solutions | 20 | 80 |
| 50090-1200-02 | Q0162 | A-S Medication Solutions | 5 | 20 |
| 50090-1200-03 | Q0162 | A-S Medication Solutions | 30 | 120 |
| 50090-1201-00 | Q0162 | A-S Medication Solutions | 10 | 40 |
| 50090-1658-00 | Q0162 | A-S Medication Solutions | 10 | 40 |
| 50090-1658-01 | Q0162 | A-S Medication Solutions | 20 | 80 |
| 50090-1658-02 | Q0162 | A-S Medication Solutions | 5 | 20 |
| 50090-1658-03 | Q0162 | A-S Medication Solutions | 30 | 120 |
| 50090-1659-00 | Q0162 | A-S Medication Solutions | 10 | 40 |
| 50090-1660-00 | Q0162 | A-S Medication Solutions | 4 | 32 |
| 50090-1660-01 | Q0162 | A-S Medication Solutions | 30 | 240 |
| 50090-1660-02 | Q0162 | A-S Medication Solutions | 10 | 80 |
| 50090-1660-03 | Q0162 | A-S Medication Solutions | 20 | 160 |
| 50090-2343-00 | Q0162 | A-S Medication Solutions | 10 | 40 |
| 50090-2343-01 | Q0162 | A-S Medication Solutions | 20 | 80 |
| 50090-2343-02 | Q0162 | A-S Medication Solutions | 5 | 20 |
| 50090-2343-03 | Q0162 | A-S Medication Solutions | 30 | 120 |
| 50090-4632-00 | Q0162 | A-S Medication Solutions | 4 | 32 |
| 50090-4632-01 | Q0162 | A-S Medication Solutions | 30 | 240 |
| 50090-4632-02 | Q0162 | A-S Medication Solutions | 10 | 80 |
| 50090-4632-03 | Q0162 | A-S Medication Solutions | 20 | 160 |
| 50090-5346-01 | Q0162 | A-S Medication Solutions | 30 | 240 |
| 50090-5346-02 | Q0162 | A-S Medication Solutions | 10 | 80 |
| 50090-5346-03 | Q0162 | A-S Medication Solutions | 20 | 160 |
| 62135-0121-30 | Q0162 | Chartwell | 30 | 120 |
| 62135-0122-30 | Q0162 | Chartwell | 30 | 240 |
| 68001-0246-04 | Q0162 | BluePoint Laboratories | 30 | 120 |
| 68001-0246-17 | Q0162 | BluePoint Laboratories | 30 | 120 |
| 68001-0247-04 | Q0162 | BluePoint Laboratories | 30 | 240 |
| 68001-0247-17 | Q0162 | BluePoint Laboratories | 30 | 240 |
| 68462-0157-13 | Q0162 | Glenmark Pharmaceuticals Inc., USA | 30 | 120 |
| 68462-0158-11 | Q0162 | Glenmark Pharmaceuticals Inc., USA | 10 | 80 |
| 68462-0158-13 | Q0162 | Glenmark Pharmaceuticals Inc., USA | 30 | 240 |
| 68788-7565-01 | Q0162 | Preferred Pharmaceuticals Inc | 10 | 80 |
| 68788-7565-03 | Q0162 | Preferred Pharmaceuticals Inc | 30 | 240 |
| 68788-7644-01 | Q0162 | Preferred Pharmaceuticals Inc | 10 | 40 |
| 68788-7644-03 | Q0162 | Preferred Pharmaceuticals Inc | 30 | 120 |
| 68788-8666-01 | Q0162 | Preferred Pharmaceuticals Inc | 10 | 40 |
| 68788-8666-03 | Q0162 | PREFERRED PHARMACEUTICALS, INC. | 30 | 120 |
| 68788-9559-01 | Q0162 | Preferred Pharmaceuticals Inc | 10 | 80 |
| 68788-9559-03 | Q0162 | Preferred Pharmaceuticals Inc | 30 | 240 |
| 72336-0073-30 | Q0162 | Lifsa Drugs LLC | 30 | 480 |
Ondansetron ODT: common questions
- What is the HCPCS code for Ondansetron ODT?
- Ondansetron ODT is billed under HCPCS Q0162 — Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen. One billing unit is 1 mg. CMS's crosswalk lists 55 Ondansetron ODT NDCs under this code.
- How many Q0162 billing units are in a package of Ondansetron ODT?
- CMS lists 8 to 480 billing units per package, depending on the NDC, where one unit is 1 mg. Units to report are based on the dose given, not the package.
- Is Q0162 a CPT code?
- No. Q0162 is a HCPCS Level II code from CMS for the drug itself. Giving it, for example by injection or infusion, is usually reported with a separate CPT administration code.